Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternative Adjuvant Chemotherapy for Operable Breast Cancer Non-responsive to Primary Chemotherapy
NCT01019616Phase 3Unknown
- Start
- Mar 2011
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in breast cancer (2 arms). Primary endpoint: Distant Disease-Free Survival at 3 years. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01019616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01019616.